University of CO Hospital
- Type
- Teaching hospital
- Where
- Arvada, CO
- Medicare CCN
- 060024
- Received
- $5,432,198 in 150 records, 2021 ($252,701 general, $5,179,497 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 45 | $252,701 |
| 2021 | Research payment | 105 | $5,179,497 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 105 | $5,179,497 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 24 | $108,301 |
| Grant | 6 | $57,810 |
| Education | 3 | $35,527 |
| Consulting Fee | 4 | $20,139 |
| Long term medical supply or device loan | 2 | $20,000 |
| Gift | 1 | $4,673 |
| Space rental or facility fees (teaching hospital only) | 1 | $3,269 |
| Royalty or License | 2 | $2,597 |
| Debt forgiveness | 2 | $381 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | AngioDynamics, Inc. | $18,500 | Education | In-kind items and services | Auryon Laser System 100-120 Vac Device, ET | 2021 | |
| 2021-12-31 | Intuitive Surgical, Inc. | $16,260 | Long term medical supply or device loan | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-12-31 | Intuitive Surgical, Inc. | $4,673 | Gift | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-12-31 | Intuitive Surgical, Inc. | $3,739 | Long term medical supply or device loan | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $14 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | \";A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tu | 2021 |
| 2021-12-30 | ROCHE MOLECULAR SYSTEMS, INC. | $2,724 | Research payment | In-kind items and services | cobas Influenza A/B Nucleic acid test for use on the cobas Liat System Device, Molecular Diagnostics | RD005398 | 2021 |
| 2021-12-24 | Abbott Laboratories | $3,300 | Consulting Fee | Cash or cash equivalent | EnSite Precision Cardiac Mapping System Device, Electrophysiology | 2021 | |
| 2021-12-24 | Abbott Laboratories | $1,925 | Consulting Fee | Cash or cash equivalent | EnSite Precision Cardiac Mapping System Device, Electrophysiology | 2021 | |
| 2021-12-21 | Vitalant | $221 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-12-17 | Vitalant | $1,430 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-12-15 | Kaneka Medical America LLC | $14,662 | Consulting Fee (12 payments) | Cash or cash equivalent | LIPOSORBER Device, Lipid Apheresis | 2021 | |
| 2021-12-08 | Vitalant | $460 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-12-06 | EMD Millipore Corporation | $15,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2021 | |
| 2021-12-06 | Premia Spine, Ltd. | $1,265 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2021 |
| 2021-12-03 | Vitalant | $625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments) | Cash or cash equivalent | 2021 | ||
| 2021-12-02 | ROCHE MOLECULAR SYSTEMS, INC. | $1,284 | Research payment | In-kind items and services | cobas Influenza A/B Nucleic acid test for use on the cobas Liat System Device, Molecular Diagnostics | RD005398 | 2021 |
| 2021-12-01 | PFIZER INC. | $6,750 | Research payment | In-kind items and services | 2021 | ||
| 2021-12-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $114 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2021 |
| 2021-11-30 | ROCHE MOLECULAR SYSTEMS, INC. | $2,724 | Research payment | In-kind items and services | cobas Influenza A/B Nucleic acid test for use on the cobas Liat System Device, Molecular Diagnostics | RD005398 | 2021 |
| 2021-11-19 | Vitalant | $1,575 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-11-17 | ACUMED LLC | $2,500 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-11-01 | Skeletal Dynamics Inc | $21,500 | Grant | Cash or cash equivalent | Geminus Device, Orthopedic | 2021 | |
| 2021-11-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $116 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2021 |
| 2021-10-29 | ROCHE MOLECULAR SYSTEMS, INC. | $2,724 | Research payment | In-kind items and services | cobas Influenza A/B Nucleic acid test for use on the cobas Liat System Device, Molecular Diagnostics | RD005398 | 2021 |
| 2021-10-26 | Boehringer Ingelheim France S.A.S. | $488 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-10-22 | Vitalant | $2,205 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-10-08 | LENOSS MEDICAL INC | $22,672 | Research payment | Cash or cash equivalent | Access & Cavity Creation Kit Device, Spinal Surgery | The Biological Allograft Chain Tissue Implant & Associated Manual Surgical Instrumentation: A Prospective, Post-Market S | 2021 |
| 2021-10-07 | Premia Spine, Ltd. | $4,229 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2021 |
| 2021-10-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $116 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2021 |
| 2021-09-28 | HEARTFLOW, INC. | $3,538 | Research payment | Cash or cash equivalent | FFRct Device, Coronory | 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 424 PRECISE | 2021 |
| 2021-09-27 | SERVIER PHARMACEUTICALS LLC | $567,600 | Research payment | In-kind items and services | TIBSOVO Drug, ONCOLOGY | STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMA, WITH AN IDH1 MUTATION | 2021 |
| 2021-09-24 | Vitalant | $1,962 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments) | Cash or cash equivalent | 2021 | ||
| 2021-09-20 | ROCHE MOLECULAR SYSTEMS, INC. | $2,724 | Research payment | In-kind items and services | cobas Influenza A/B Nucleic acid test for use on the cobas Liat System Device, Molecular Diagnostics | RD005398 | 2021 |
| 2021-09-18 | Aspire Bariatrics, Inc. | $4,150 | Research payment | Cash or cash equivalent | AspireAssist Device, Gastroenterology | Pivotal Aspiration with Adjusted Lifestyle | 2021 |
| 2021-09-15 | ACUMED LLC | $15,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-09-10 | Abbott Laboratories | $1,934 | Research payment | In-kind items and services | FlexAbility Ablation Catheter Device, Electrophysiology | LESS-VT | 2021 |
| 2021-09-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $119 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2021 |
| 2021-09-01 | Boehringer Ingelheim France S.A.S. | $80 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-08-30 | ROCHE MOLECULAR SYSTEMS, INC. | $2,724 | Research payment | In-kind items and services | cobas Influenza A/B Nucleic acid test for use on the cobas Liat System Device, Molecular Diagnostics | RD005398 | 2021 |
| 2021-08-27 | Vitalant | $72 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-08-23 | Olympus America Inc. | $11 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-08-20 | Vitalant | $2,825 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-08-08 | Boehringer Ingelheim France S.A.S. | $34 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-08-08 | Boehringer Ingelheim France S.A.S. | $34 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-08-08 | Boehringer Ingelheim France S.A.S. | $34 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-08-08 | Boehringer Ingelheim France S.A.S. | $34 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-08-08 | Boehringer Ingelheim France S.A.S. | $34 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-08-06 | Integra LifeSciences Corporation | $1,600 | Grant | Cash or cash equivalent | MAYFIELD Device, PRECISION TOOLS & INSTRUMENTS | 2021 | |
| 2021-08-03 | E.R. Squibb & Sons, L.L.C. | $100,188 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant Melanoma Stage II B C Opdivo Mono | 2021 |
| 2021-08-02 | SERVIER PHARMACEUTICALS LLC | $794,640 | Research payment | In-kind items and services | TIBSOVO Drug, ONCOLOGY | STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMA, WITH AN IDH1 MUTATION | 2021 |
| 2021-08-02 | SERVIER PHARMACEUTICALS LLC | $567,600 | Research payment | In-kind items and services | TIBSOVO Drug, ONCOLOGY | STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMA, WITH AN IDH1 MUTATION | 2021 |
| 2021-08-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $119 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2021 |
| 2021-08-01 | Boehringer Ingelheim France S.A.S. | $81 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-07-30 | ROCHE MOLECULAR SYSTEMS, INC. | $2,724 | Research payment | In-kind items and services | cobas Influenza A/B Nucleic acid test for use on the cobas Liat System Device, Molecular Diagnostics | RD005398 | 2021 |
| 2021-07-28 | AngioDynamics, Inc. | $16,833 | Education | In-kind items and services | Auryon Laser System 100-120 Vac Device, ET | 2021 | |
| 2021-07-27 | Orthofix Medical, Inc. | $2,226 | Research payment | Cash or cash equivalent | ICON Device, Thoracolumbosacral Pedicle Screw System | CP-1702SSPM- Study Using the SpinalStim Device Following Lumbar Fusion Surgery | 2021 |
| 2021-07-23 | Vitalant | $1,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-07-22 | Abbott Laboratories | $252 | Consulting Fee | Cash or cash equivalent | AMPLATZER Occluders Device, Structural Heart | 2021 | |
| 2021-07-16 | Aesculap Biologics, LLC | $22,136 | Research payment | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2021 |
| 2021-07-16 | Vitalant | $1,938 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (5 payments) | Cash or cash equivalent | 2021 | ||
| 2021-07-16 | Aesculap Biologics, LLC | $1,746 | Research payment | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2021 |
| 2021-07-07 | Boehringer Ingelheim France S.A.S. | $34 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-07-07 | Boehringer Ingelheim France S.A.S. | $34 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-07-07 | Boehringer Ingelheim France S.A.S. | $34 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-07-07 | Boehringer Ingelheim France S.A.S. | $34 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-07-07 | Boehringer Ingelheim France S.A.S. | $34 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-07-05 | EMD Millipore Corporation | $15,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2021 | |
| 2021-07-01 | ModernaTX, Inc. | $1,280 | Research payment | Cash or cash equivalent | Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulated mRNA Encoding Hu | 2021 | |
| 2021-07-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $119 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2021 |
| 2021-07-01 | Boehringer Ingelheim France S.A.S. | $81 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-06-30 | HEARTFLOW, INC. | $3,828 | Research payment | Cash or cash equivalent | FFRct Device, Coronory | 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 424 PRECISE | 2021 |
| 2021-06-29 | Siemens Medical Solutions USA, Inc. | $7,210 | Grant | In-kind items and services | 2021 | ||
| 2021-06-29 | ROCHE MOLECULAR SYSTEMS, INC. | $2,724 | Research payment | In-kind items and services | cobas Influenza A/B Nucleic acid test for use on the cobas Liat System Device, Molecular Diagnostics | RD005398 | 2021 |
| 2021-06-25 | Vitalant | $3,295 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-06-24 | Boehringer Ingelheim Pharma GmbH & Co.KG | $278 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2021 |
| 2021-06-21 | Avita Medical Americas, LLC | $256,678 | Research payment | Cash or cash equivalent | RECELL Device, Mechanical and Enzymatic Autologous Skin Processor For Cell Suspension, With Applicator | Study of delivery of gene-modified skin cells to patients with epidermolysis bullosa. | 2021 |
| 2021-06-17 | FUJIFILM SonoSite, Inc. | $194 | Education | In-kind items and services | SonoSite Edge II Device, Medical Device | 2021 | |
| 2021-06-11 | Vitalant | $1,124 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments) | Cash or cash equivalent | 2021 | ||
| 2021-06-08 | Orthofix Medical, Inc. | $20,205 | Research payment | Cash or cash equivalent | M6-C Device, Prosthesis, Intervertebral Disc | M6-C Post Approval Study (PAS)- CA-C004 | 2021 |
| 2021-06-06 | Boehringer Ingelheim France S.A.S. | $178 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-06-03 | E.R. Squibb & Sons, L.L.C. | $19,774 | Research payment | Cash or cash equivalent | Phase I II TIM3 FIH Monotherapy Nivo Combination in advanced solid tumors | 2021 | |
| 2021-06-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $123 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2021 |
| 2021-06-01 | Boehringer Ingelheim France S.A.S. | $83 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-05-28 | ROCHE MOLECULAR SYSTEMS, INC. | $2,724 | Research payment | In-kind items and services | cobas Influenza A/B Nucleic acid test for use on the cobas Liat System Device, Molecular Diagnostics | RD005398 | 2021 |
| 2021-05-26 | Boehringer Ingelheim France S.A.S. | $509 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-05-24 | EMD Millipore Corporation | $15,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2021 | |
| 2021-05-20 | Orthofix Medical, Inc. | $7,538 | Research payment | Cash or cash equivalent | ICON Device, Thoracolumbosacral Pedicle Screw System | CP-1702SSPM- Study Using the SpinalStim Device Following Lumbar Fusion Surgery | 2021 |
| 2021-05-20 | Orthofix Medical, Inc. | $3,084 | Research payment | Cash or cash equivalent | ICON Device, Thoracolumbosacral Pedicle Screw System | CP-1702SSPM- Study Using the SpinalStim Device Following Lumbar Fusion Surgery | 2021 |
| 2021-05-20 | Vitalant | $1,455 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-05-18 | Orthofix Medical, Inc. | $10,926 | Research payment | Cash or cash equivalent | M6-C Device, Prosthesis, Intervertebral Disc | M6-C Post Approval Study (PAS)- CA-C004 | 2021 |
| 2021-05-18 | E.R. Squibb & Sons, L.L.C. | $1,280 | Research payment | Cash or cash equivalent | Ph II Study Gastric 1L, multi-cohort all comers lag3 nivo | 2021 | |
| 2021-05-10 | Eli Lilly and Company | $65 | Research payment | In-kind items and services | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC L | 2021 | |
| 2021-05-06 | Integra LifeSciences Corporation | $10,000 | Grant | Cash or cash equivalent | MICROFRANCE Device, PRECISION TOOLS & INSTRUMENTS | 2021 | |
| 2021-05-05 | Boehringer Ingelheim France S.A.S. | $176 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-05-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $121 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2021 |
| 2021-05-01 | Boehringer Ingelheim France S.A.S. | $82 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-04-30 | Eli Lilly and Company | $50 | Research payment | In-kind items and services | A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES A | 2021 | |
| 2021-04-28 | ROCHE MOLECULAR SYSTEMS, INC. | $2,724 | Research payment | In-kind items and services | cobas Influenza A/B Nucleic acid test for use on the cobas Liat System Device, Molecular Diagnostics | RD005398 | 2021 |
| 2021-04-23 | Vitalant | $6,640 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (4 payments) | Cash or cash equivalent | 2021 | ||
| 2021-04-20 | Orthofix Medical, Inc. | $3,942 | Research payment | Cash or cash equivalent | ICON Device, Thoracolumbosacral Pedicle Screw System | CP-1702SSPM- Study Using the SpinalStim Device Following Lumbar Fusion Surgery | 2021 |
| 2021-04-16 | E.R. Squibb & Sons, L.L.C. | $9,159 | Research payment | Cash or cash equivalent | Ph I IIA FIH mono& combo Tx Solid Tumor | 2021 | |
| 2021-04-15 | Orthofix Medical, Inc. | $4,748 | Research payment | Cash or cash equivalent | Physio-Stim Device, Stimulator, Bone Growth, Non-Invasive | CP-1703 CSPM- Study Using the CervicalStim Device Following Cervical Fusion | 2021 |
| 2021-04-14 | AstraZeneca Pharmaceuticals LP | $1,200 | Research payment | Cash or cash equivalent | TAGRISSO Drug, Oncology | \";A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tu | 2021 |
| 2021-04-12 | SERVIER PHARMACEUTICALS LLC | $794,640 | Research payment | In-kind items and services | TIBSOVO Drug, ONCOLOGY | STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMA, WITH AN IDH1 MUTATION | 2021 |
| 2021-04-12 | SERVIER PHARMACEUTICALS LLC | $567,600 | Research payment | In-kind items and services | TIBSOVO Drug, ONCOLOGY | STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMA, WITH AN IDH1 MUTATION | 2021 |
| 2021-04-08 | Orthofix Medical, Inc. | $2,752 | Research payment | Cash or cash equivalent | ICON Device, Thoracolumbosacral Pedicle Screw System | CP-1702SSPM- Study Using the SpinalStim Device Following Lumbar Fusion Surgery | 2021 |
| 2021-04-08 | ROCHE MOLECULAR SYSTEMS, INC. | $851 | Research payment | In-kind items and services | cobas Influenza A/B Nucleic acid test for use on the cobas Liat System Device, Molecular Diagnostics | RD005398 | 2021 |
| 2021-04-08 | Eli Lilly and Company | $30 | Research payment | In-kind items and services | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN L | 2021 | |
| 2021-04-07 | E.R. Squibb & Sons, L.L.C. | $193,759 | Research payment | Cash or cash equivalent | Phase I II CTLA4-NF-Probody FIH Mono Nivo Combo in advanced solid tumors | 2021 | |
| 2021-04-07 | E.R. Squibb & Sons, L.L.C. | $27,628 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant HCC mono vs placebo | 2021 |
| 2021-04-04 | Smith+Nephew, Inc. | $370 | Debt forgiveness | Cash or cash equivalent | ACUFEX Access Pat Pos Device, Sports Med Shoulder | 2021 | |
| 2021-04-04 | Boehringer Ingelheim France S.A.S. | $172 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-04-02 | Vitalant | $2,060 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (3 payments) | Cash or cash equivalent | 2021 | ||
| 2021-04-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $118 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2021 |
| 2021-04-01 | Boehringer Ingelheim France S.A.S. | $80 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-03-30 | ROCHE MOLECULAR SYSTEMS, INC. | $2,724 | Research payment | In-kind items and services | cobas Influenza A/B Nucleic acid test for use on the cobas Liat System Device, Molecular Diagnostics | RD005398 | 2021 |
| 2021-03-26 | Vitalant | $1,575 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-03-18 | E.R. Squibb & Sons, L.L.C. | $67,867 | Research payment | Cash or cash equivalent | Progressive Combinations- Metastatic ER HER2- Breast Cancer | 2021 | |
| 2021-03-10 | ACUMED LLC | $3,269 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Elbow Plating System Device, Elbow | 2021 | |
| 2021-03-08 | E.R. Squibb & Sons, L.L.C. | $121,991 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | 2016-NIV-0532 PD-1 Immune Checkpoint Inhibition for the Prevention of Lung Cancer in Hi Risk Current and Former Smokers | 2021 |
| 2021-03-03 | Varian Medical Systems, Inc. | $31,358 | Research payment | Cash or cash equivalent | Immune responses to focal therapy for early prostate cancer - U. of Colorado | 2021 | |
| 2021-03-03 | Boehringer Ingelheim France S.A.S. | $177 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $122 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2021 |
| 2021-03-01 | Boehringer Ingelheim France S.A.S. | $82 | Research payment | In-kind items and services | Ph IIb dose finding vs placebo in patients with Obesity | 2021 | |
| 2021-02-26 | ROCHE MOLECULAR SYSTEMS, INC. | $2,724 | Research payment | In-kind items and services | cobas Influenza A/B Nucleic acid test for use on the cobas Liat System Device, Molecular Diagnostics | RD005398 | 2021 |
| 2021-02-26 | Vitalant | $1,668 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments) | Cash or cash equivalent | 2021 | ||
| 2021-02-19 | E.R. Squibb & Sons, L.L.C. | $61,362 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase IIA Dara Nivo in Solid Tumors NSCLC, TNBC, PAC | 2021 |
| 2021-02-16 | EMD Millipore Corporation | $2,541 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2021 | |
| 2021-02-16 | EMD Millipore Corporation | $56 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2021 | |
| 2021-02-09 | E.R. Squibb & Sons, L.L.C. | $120,178 | Research payment | Cash or cash equivalent | PhI II Other I-O Triplet lag3 nivo ipi vs lag3 nivo IDO | 2021 | |
| 2021-02-09 | E.R. Squibb & Sons, L.L.C. | $2,284 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III 1L Gastric nivo ipi vs nivo CT vs CT | 2021 |
| 2021-02-02 | E.R. Squibb & Sons, L.L.C. | $35,027 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III NMIBC Opdivo BCG vs. BCG | 2021 |
| 2021-02-01 | EMD Millipore Corporation | $15,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2021 | |
| 2021-02-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $122 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2021 |
| 2021-01-30 | ROCHE MOLECULAR SYSTEMS, INC. | $2,724 | Research payment | In-kind items and services | cobas Influenza A/B Nucleic acid test for use on the cobas Liat System Device, Molecular Diagnostics | RD005398 | 2021 |
| 2021-01-29 | Eli Lilly and Company | $5,270 | Research payment | In-kind items and services | A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+, H | 2021 | |
| 2021-01-26 | E.R. Squibb & Sons, L.L.C. | $1,260 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III RCC Monotherapy vs. everolimus ONO 4538-03 | 2021 |
| 2021-01-22 | Vitalant | $270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-01-21 | EMD Millipore Corporation | $15,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2021 | |
| 2021-01-14 | Eli Lilly and Company | $1,215 | Research payment | In-kind items and services | A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 | 2021 | |
| 2021-01-12 | Biotest AG | $1,701 | Research payment | Cash or cash equivalent | An Open-label, Prospective, Multicenter Study Investigating Clinical Efficacy, Safety, and Pharmacokinetic Properties of | 2021 | |
| 2021-01-07 | E.R. Squibb & Sons, L.L.C. | $204,327 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Nivo Ipi vs Placebo in Adjuvant RCC | 2021 |
| 2021-01-07 | Premia Spine, Ltd. | $4,155 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2021 |
| 2021-01-05 | E.R. Squibb & Sons, L.L.C. | $238,562 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Nivo ipi vs Nivo in Stage IIIb c or IV Adjuvant Melanoma | 2021 |
| 2021-01-05 | E.R. Squibb & Sons, L.L.C. | $67,331 | Research payment | Cash or cash equivalent | Phase FIH CCR2-5 I II Safety Expansion | 2021 | |
| 2021-01-05 | E.R. Squibb & Sons, L.L.C. | $58,257 | Research payment | Cash or cash equivalent | Ph III 1L Metastatic Melanoma nivo NKTR 214 vs nivo mono | 2021 | |
| 2021-01-05 | E.R. Squibb & Sons, L.L.C. | $42,887 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III 1L Metastatic RCC Nivo Ipi Cabo | 2021 |
| 2021-01-05 | E.R. Squibb & Sons, L.L.C. | $21,856 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase II III 1L MSS CRC Nivo SOC vs SOC | 2021 |
| 2021-01-04 | E.R. Squibb & Sons, L.L.C. | $22,577 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Study Adj GEJ & Esoph US EU mono | 2021 |
| 2021-01-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $122 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Arvada, CO, county Jefferson County, CO, state Colorado; placed by its city name.
| Measure | Place (city or town) Arvada, CO | County Jefferson County, CO | State Colorado |
|---|---|---|---|
| Population B01003 | 122,634 | 579,377 | 5,862,189 |
| Population, 2020 census P1 | 124,402 | 582,910 | 5,773,714 |
| Median age B01002 | 40.0 | 40.5 | 37.7 |
| Under 18 B01001 | 19.6% | 18.5% | 21.0% |
| 65 and over B01001 | 17.4% | 17.9% | 15.6% |
| Households B11001 | 49,881 | 241,735 | 2,374,218 |
| Foreign born B05002 | 5.6% | 6.3% | 9.8% |
| Median household income B19013 | $117,348 | $110,656 | $95,470 |
| Median family income B19113 | $143,746 | $138,654 | $119,139 |
| Per capita income B19301 | $59,662 | $60,827 | $52,636 |
| Poverty rate B17001 | 5.8% | 6.7% | 9.4% |
| Unemployment rate B23025 | 3.8% | 3.9% | 4.6% |
| Civilian labor force B23025 | 71,860 | 336,266 | 3,235,476 |
| Mean commute (minutes) B08013 | 26.1 | 26.0 | 25.2 |
| Bachelor's degree or higher B15003 | 51.6% | 52.0% | 45.7% |
| Housing units B25001 | 52,169 | 253,574 | 2,589,053 |
| Owner-occupied B25003 | 75.3% | 70.7% | 66.2% |
| Renters B25003 | 24.7% | 29.3% | 33.8% |
| Median home value B25077 | $632,600 | $637,600 | $539,400 |
| Median gross rent B25064 | $1,888 | $1,861 | $1,761 |
| White, not Hispanic B03002 | 76.0% | 75.2% | 64.8% |
| Black B03002 | 1.0% | 1.1% | 3.8% |
| Hispanic or Latino B03002 | 15.8% | 16.1% | 22.5% |
| Asian B03002 | 2.6% | 2.9% | 3.2% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.4% |
Economy now FRED unemployment 4.1% in Sep 2026 (3.8% a year earlier); per capita personal income $86,342 in 2025, up 34% in five years (+7.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Arvada, CO.
Comments